Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin

Journal of Infectious Diseases

Volumn 193, Issue 6, 2006, Pages 796-801

  Goudsmit, Jasp ^a   Marissen, Wilfred E ^a   Weldon, William C ^c   Niezgoda, Michael ^c   Hanlon, Cathleen A ^c   Rice, Amy B ^b   De Kruif, John ^a   Dietzschold, Bernhard ^b   Bakker, Alexander B H ^a   Rupprecht, Charles E ^c  

^a CRUCELL HOLLAND BV   (Netherlands)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPLOID CELL VACCINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CR4098; MONOCLONAL ANTIBODY CR57; POLYCLONAL ANTIBODY; RABIES IMMUNOGLOBULIN; RABIES VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DOG BITE; DOSE RESPONSE; ENDEMIC DISEASE; IMMUNOGENICITY; INFECTION CONTROL; KAPLAN MEIER METHOD; MOUSE; NONHUMAN; PRIORITY JOURNAL; RABIES; RABIES VIRUS; SYRIAN HAMSTER; VIRUS NEUTRALIZATION; WORLD HEALTH ORGANIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CELL LINE; CRICETINAE; HUMANS; IMMUNOGLOBULINS; IMMUNOTHERAPY; MESOCRICETUS; RABIES; RABIES VACCINES; RABIES VIRUS;

EID: 33644915794     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/500470     Document Type: Article

References (23)

1. Knobel DL, Cleaveland S, Coleman PG, et al. Re-evaluating the burden of rabies in Africa and Asia. Bull World Health Organ 2005; 83:360-8.
2. Coleman PG, Fevre EM, Cleaveland S. Estimating the public health impact of rabies. Emerg Infect Dis 2004; 10:140-2.
3. Montano-Hirose JA, Lafage M, Weber P, Badrane H, Tordo N, Lafon M. Protective activity of a murine monoclonal antibody against European bat lyssavirus 1 (EBL1) infection in mice. Vaccine 1993; 11:1259-66.
4. Hanlon CA, Niezgoda M, Rupprecht CE. Postexposure prophylaxis for prevention of rabies in dogs. Am J Vet Res 2002; 63:1096-100.
5. Hanlon CA, DeMattos CA, DeMattos CC, et al. Experimental utility of rabies virus-neutralizing human monoclonal antibodies in post-exposure prophylaxis. Vaccine 2001; 19:3834-42.
6. Prosniak M, Faber M, Hanlon CA, Rupprecht CE, Hooper DC, Dietzschold B. Development of a cocktail of recombinant-expressed human rabies virus-neutralizing monoclonal antibodies for postexposure prophylaxis of rabies. J Infect Dis 2003; 188:53-6.
7. Schumacher CL, Dietzschold B, Ertl HC, Niu HS, Rupprecht CE, Koprowski H. Use of mouse anti-rabies monoclonal antibodies in post-exposure treatment of rabies. J Clin Invest 1989; 84:971-5.
8. Dietzschold B, Gore M, Casali P, et al. Biological characterization of human monoclonal antibodies to rabies virus. J Virol 1990; 64:3087-90.
9. Enssle K, Kurrle R, Kohler R, et al. A rabies-specific human monoclonal antibody that protects mice against lethal rabies. Hybridoma 1991; 10:547-56.
10. Marissen WE, Kramer RA, Rice A, et al. Novel rabies virus-neutralizing epitope recognized by human monoclonal antibody: fine mapping and escape mutant analysis. J Virol 2005; 79:4672-8.
11. Bakker AB, Marissen WE, Kramer RA, et al. Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants. J Virol 2005; 79:9062-8.
12. Kramer RA, Marissen WE, Goudsmit J, et al. The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries. Eur J Immunol 2005; 35:2131-45.
13. Fallaux FJ, Bout A, van der Velde I, et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther 1998; 9:1909-17.
14. Jones D, Kroos N, Anema R, et al. High-level expression of recombinant IgG in the human cell line PER.C6. Biotechnol Prog 2003; 19:163-8.
15. Smith JS, Yager PA, Baer GM. A rapid fluorescent focus inhibition test (RFFIT) for determining rabies virus-neutralizing antibody. In: Meslin F-X, Kaplan MM, Koprowski H, eds. Laboratory techniques in rabies. 4th ed. Geneva, Switzerland: World Health Organization 1996;181-192.
16. Hanlon CA, Niezgoda M, Morrill PA, Rupprecht CE. The incurable wound revisited: progress in human rabies prevention? Vaccine 2001; 19:2273-9.
17. National Institutes of Health. Guide for the care and use of laboratory animals. Washington, DC: National Academy Press, 1996.
18. Centers for Disease Control and Prevention. Protocol for postmortem diagnosis of rabies in animals by direct fluorescent antibody testing. Available at: http://www.cdc.gov/ncidod/dvrd/rabies/professional/publications/ DFA_diagnosis/DFA_protocol-b.htm. Accessed 25 July 2005.
19. Atanasiu P, Bahmanyar M, Baltazard M, et al. Rabies neutralizing antibody response to different schedules of serum and vaccine inoculations in non-exposed persons. Bull World Health Organ 1956; 14:593-611.
20. Atanasiu P, Bahmanyar M, Baltazard M, et al. Rabies neutralizing antibody response to different schedules of serum and vaccine inoculations in non-exposed persons. II. Bull World Health Organ 1957; 17:911-32.
21. Atanasiu P, Cannon DA, Dean DJ, et al. Rabies neutralizing antibody response to different schedules of serum and vaccine inoculations in non-exposed persons. 3. Bull World Health Organ 1961; 25:103-14.
22. Atanasiu P, Dean DJ, Habel K, et al. Rabies neutralizing antibody response to different schedules of serum and vaccine inoculations in non-exposed persons. 4. Bull World Health Organ 1967; 36:361-5.
23. Wiktor TJ, Lerner RA, Koprowski H. Inhibitory effect of passive antibody on active immunity induced against rabies by vaccination. Bull World Health Organ 1971; 45:747-53.